company background image
IDOG

Idogen OM:IDOGEN Stock Report

Last Price

kr0.30

Market Cap

kr21.8m

7D

1.7%

1Y

-92.0%

Updated

26 Jun, 2022

Data

Company Financials
IDOGEN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

IDOGEN Stock Overview

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden.

Idogen Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Idogen
Historical stock prices
Current Share Pricekr0.30
52 Week Highkr3.80
52 Week Lowkr0.27
Beta1.5
1 Month Change-24.24%
3 Month Change-50.98%
1 Year Change-91.98%
3 Year Change-98.21%
5 Year Change-99.48%
Change since IPO-99.56%

Recent News & Updates

Shareholder Returns

IDOGENSE BiotechsSE Market
7D1.7%1.5%-1.3%
1Y-92.0%-20.4%-23.6%

Return vs Industry: IDOGEN underperformed the Swedish Biotechs industry which returned -20.4% over the past year.

Return vs Market: IDOGEN underperformed the Swedish Market which returned -23.6% over the past year.

Price Volatility

Is IDOGEN's price volatile compared to industry and market?
IDOGEN volatility
IDOGEN Average Weekly Movement9.1%
Biotechs Industry Average Movement8.1%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market4.7%

Stable Share Price: IDOGEN is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: IDOGEN's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200812Anders Karlssonhttps://www.idogen.com

Idogen AB (publ), a biotechnology company, develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs, and the body’s own cells or tissues in Sweden. The company’s advanced product candidate is IDO 8 that is designed for patients with severe haemophilia A, who have developed neutralizing antibodies against critical treatment with coagulation factor VIII. It also develops IDO T, a tolerogenic cell therapy to prevent organ transplant rejection primarily kidney transplantation; and IDO AID for the treatment of autoimmune diseases.

Idogen Fundamentals Summary

How do Idogen's earnings and revenue compare to its market cap?
IDOGEN fundamental statistics
Market Capkr21.75m
Earnings (TTM)-kr39.01m
Revenue (TTM)kr12.24m

1.8x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IDOGEN income statement (TTM)
Revenuekr12.24m
Cost of Revenuekr0
Gross Profitkr12.24m
Other Expenseskr51.25m
Earnings-kr39.01m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 25, 2022

Earnings per share (EPS)-0.54
Gross Margin100.00%
Net Profit Margin-318.85%
Debt/Equity Ratio0.0%

How did IDOGEN perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IDOGEN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDOGEN?

Other financial metrics that can be useful for relative valuation.

IDOGEN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does IDOGEN's PS Ratio compare to its peers?

IDOGEN PS Ratio vs Peers
The above table shows the PS ratio for IDOGEN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average7.3x

Price-To-Sales vs Peers: IDOGEN is good value based on its Price-To-Sales Ratio (1.8x) compared to the peer average (7.3x).


Price to Earnings Ratio vs Industry

How does IDOGEN's PE Ratio compare vs other companies in the SE Biotechs Industry?

Price-To-Sales vs Industry: IDOGEN is good value based on its Price-To-Sales Ratio (1.8x) compared to the Swedish Biotechs industry average (19.1x)


Price to Sales Ratio vs Fair Ratio

What is IDOGEN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDOGEN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate IDOGEN's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IDOGEN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IDOGEN's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IDOGEN's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDOGEN's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Idogen forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


34.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Idogen has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Take a look at our analysis of IDOGEN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Idogen competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Idogen performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-13.1%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IDOGEN is currently unprofitable.

Growing Profit Margin: IDOGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IDOGEN is unprofitable, and losses have increased over the past 5 years at a rate of 13.1% per year.

Accelerating Growth: Unable to compare IDOGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IDOGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).


Return on Equity

High ROE: IDOGEN has a negative Return on Equity (-94.18%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Idogen's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IDOGEN's short term assets (SEK45.1M) exceed its short term liabilities (SEK4.6M).

Long Term Liabilities: IDOGEN's short term assets (SEK45.1M) do not cover its long term liabilities (SEK-1,000.0).


Debt to Equity History and Analysis

Debt Level: IDOGEN is debt free.

Reducing Debt: IDOGEN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDOGEN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IDOGEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 20.8% each year


Discover healthy companies

Dividend

What is Idogen current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IDOGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IDOGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IDOGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IDOGEN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IDOGEN has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Anders Karlsson (57 yo)

2.83yrs

Tenure

kr2,715,000

Compensation

Mr. Anders Karlsson, M.B.A., has been Chief Executive Officer and Managing Director of Idogen AB (publ) since August 19, 2019. Mr. Karlsson served as the Chairman of the Board and Chief Executive Officer o...


CEO Compensation Analysis

Compensation vs Market: Anders's total compensation ($USD268.11K) is about average for companies of similar size in the Swedish market ($USD233.45K).

Compensation vs Earnings: Anders's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IDOGEN's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: IDOGEN's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 297.4%.


Top Shareholders

Company Information

Idogen AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Idogen AB (publ)
  • Ticker: IDOGEN
  • Exchange: OM
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr21.752m
  • Shares outstanding: 72.51m
  • Website: https://www.idogen.com

Number of Employees


Location

  • Idogen AB (publ)
  • Medicon Village
  • ScheelevAegen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/23 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.